Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
4.71
USD
-4.85%
-10.46%
+4.20%
ProPhase Labs, Inc.'s Equity Buyback announced on March 15, 2023, has expired with 69,628 shares, representing 0.43% for $0.59 million.
The company expired its plan on September 15, 2023.
Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup
Apr. 16
DJ
ProPhase Labs, Inc. Unveils Project ZenQ-AI
Apr. 16
CI
Transcript : ProPhase Labs, Inc., 2023 Earnings Call, Mar 15, 2024
Mar. 15
ProPhase Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 15
CI
North American Morning Briefing : Inflation -2-
Mar. 15
DJ
Prophase Labs, Inc. Announces Important Developments in the Company?s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test
Feb. 20
CI
ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir
Feb. 14
CI
ProPhase Labs Names Jed Latkin as Chief Operating Officer
Jan. 04
MT
ProPhase Labs, Inc. Appoints Jed Latkin as COO
Jan. 04
CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023.
Nov. 13
CI
HC Wainwright Cuts Price Target on ProPhase Labs to $11 From $14, Maintains Buy Rating
Nov. 10
MT
Transcript : ProPhase Labs, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Earnings Flash (PRPH) PROPHASE LABS Posts Q3 Revenue $8.4M
Nov. 09
MT
ProPhase Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
ProPhase Labs, Inc.'s Equity Buyback announced on March 15, 2023, has expired with 69,628 shares, representing 0.43% for $0.59 million.
23-09-14
CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023.
23-08-11
CI
Transcript : ProPhase Labs, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Earnings Flash (PRPH) PROPHASE LABS Reports Q2 Revenue $13.2M
23-08-10
MT
ProPhase Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets
23-06-30
MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected
23-06-29
MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.
23-06-28
CI
ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1
23-06-01
CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on July 26, 2022.
23-05-12
CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023.
23-05-12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
More about the company
1st Jan change
Capi.
+4.20% 84.99M -17.89% 8.25B +39.20% 3.58B -39.11% 2.46B -8.06% 2.46B -7.35% 2.38B -19.01% 1.55B -40.66% 1.21B +7.56% 1.11B -15.34% 1.03B
Medical & Diagnostic Laboratories
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1